Mycoprotein Innovator The Protein Brewery Secures €30M, Targets US Market Expansion
October 18, 2025, 9:38 am
Location: Denmark, Capital Region of Denmark, Gentofte Municipality
Employees: 51-200
Founded date: 1999
The Protein Brewery, a Dutch mycoprotein innovator, secured €30M in Series B funding. This capital fuels global expansion, targeting US and European markets with its proprietary Fermotein ingredient. The company strategically pivoted to active nutrition and healthy aging, emphasizing customer validation and sustainable, cost-effective production. New CEO Thijs Bosch navigated a complex fundraise. The investment propels advanced food solutions and addresses critical scalability hurdles in alternative proteins, charting a path for significant market impact and a redefined food future.
The Protein Brewery secured €30 million in Series B funding. This Dutch food tech innovator leads the sector. The substantial investment propels its global mission. It redefines food production. Sustainable protein solutions are its focus. Fermotein, its proprietary mycoprotein, drives this ambition. This funding round is pivotal for alternative proteins. It signals strong investor confidence. Fungi-based solutions gain traction. The capital fuels expansion into key markets. The United States is a primary target.
New investors joined the round. Invest-NL and the Brabant Development Agency (BOM) led the charge. Existing backers showed support. Novo Holdings, Unovis Asset Management, and Madeli participated. This diverse investor base reflects broad confidence. Funds are earmarked for critical initiatives. They advance Fermotein development. Commercial presence will strengthen. Production capacity at the Mijkenbroek facility expands. An innovation platform unlocks new possibilities. The Protein Brewery prepares for significant growth.
Fermotein is The Protein Brewery’s flagship. It is a fungi-based food ingredient. It boasts high protein and fiber content. It also possesses unique sensory properties. Fermotein is tasteless and odorless. This makes it highly versatile. It integrates seamlessly into various products. Applications include baked goods, snacks, and dairy alternatives. Protein shakes, functional bars, and meal replacement drinks also benefit. The company explores its role in satiety. Metabolic health pathways, including GLP-1, are under investigation. This ingredient offers broad health benefits.
Fermotein production uses a proprietary fungal strain. This method offers significant advantages. It requires low capital investment. Production is highly cost-effective. This innovative approach tackles industry hurdles. Affordability and scalability often limit alternative proteins. The Protein Brewery overcomes these challenges. Its process ensures accessibility. Sustainable production is a core tenet. It uses minimal land, water, and CO2. This commitment resonates with investors. It is a key selling point.
The Protein Brewery executed a strategic pivot. It shifted focus from alternative meat. Now, it targets active nutrition and healthy aging. This move aligns with evolving consumer demands. It opens new market segments. Global commercialization plans are aggressive. The company is launching Fermotein in the US. Several key customers will trial the product. Expansion continues in Singapore. Mycelium protein received novel food approval there last year. Preparations are underway for EU and UK market launches. Regulatory approval is the next step.
CEO Thijs Bosch spearheaded the fundraising. He joined The Protein Brewery mid-way. The 15-month fundraise was already in motion. Bosch navigated this leadership transition. Investors assessed the new strategic plan. This demonstrated remarkable agility. His leadership ensured the round's successful closure. Bosch highlighted key fundraising lessons. Customer validation proved crucial. Brand R&D and marketing validated taste and texture. This spoke directly to investors.
Investor conviction strengthened through customer feedback. Promoters spoke directly to investors. This validated commercial due diligence. Sustainability remains a core value. It acts as a "hygiene factor." Fermentation technology offers clear environmental benefits. It requires a fraction of land and water. CO2 footprint is significantly reduced. This commitment to a smaller environmental footprint still holds sway. It remains a key point for all investors. This factor reinforces the company's long-term vision.
The US market presents a significant opportunity. The Protein Brewery seeks strategic partners. These partners operate in sports and active nutrition. They also span the wellness sector. The goal is industrial-scale trials. These collaborations will accelerate market penetration. They will prove Fermotein’s versatility. They will demonstrate its effectiveness. This direct engagement fosters rapid adoption. It secures a foothold in a critical market.
This funding propels The Protein Brewery forward. It readies the company for global leadership. Its mission is clear: redefine food production. Products must be nutritious, sustainable, and scalable. They must be cost-effective. The company is now poised to accelerate. All operational building blocks are in place. The protein and fiber transition gains momentum. A strategic exit is considered more likely than an IPO. This approach offers focused growth. The Protein Brewery leads innovation. It shapes the future of food.
The Protein Brewery secured €30 million in Series B funding. This Dutch food tech innovator leads the sector. The substantial investment propels its global mission. It redefines food production. Sustainable protein solutions are its focus. Fermotein, its proprietary mycoprotein, drives this ambition. This funding round is pivotal for alternative proteins. It signals strong investor confidence. Fungi-based solutions gain traction. The capital fuels expansion into key markets. The United States is a primary target.
New investors joined the round. Invest-NL and the Brabant Development Agency (BOM) led the charge. Existing backers showed support. Novo Holdings, Unovis Asset Management, and Madeli participated. This diverse investor base reflects broad confidence. Funds are earmarked for critical initiatives. They advance Fermotein development. Commercial presence will strengthen. Production capacity at the Mijkenbroek facility expands. An innovation platform unlocks new possibilities. The Protein Brewery prepares for significant growth.
Fermotein is The Protein Brewery’s flagship. It is a fungi-based food ingredient. It boasts high protein and fiber content. It also possesses unique sensory properties. Fermotein is tasteless and odorless. This makes it highly versatile. It integrates seamlessly into various products. Applications include baked goods, snacks, and dairy alternatives. Protein shakes, functional bars, and meal replacement drinks also benefit. The company explores its role in satiety. Metabolic health pathways, including GLP-1, are under investigation. This ingredient offers broad health benefits.
Fermotein production uses a proprietary fungal strain. This method offers significant advantages. It requires low capital investment. Production is highly cost-effective. This innovative approach tackles industry hurdles. Affordability and scalability often limit alternative proteins. The Protein Brewery overcomes these challenges. Its process ensures accessibility. Sustainable production is a core tenet. It uses minimal land, water, and CO2. This commitment resonates with investors. It is a key selling point.
The Protein Brewery executed a strategic pivot. It shifted focus from alternative meat. Now, it targets active nutrition and healthy aging. This move aligns with evolving consumer demands. It opens new market segments. Global commercialization plans are aggressive. The company is launching Fermotein in the US. Several key customers will trial the product. Expansion continues in Singapore. Mycelium protein received novel food approval there last year. Preparations are underway for EU and UK market launches. Regulatory approval is the next step.
CEO Thijs Bosch spearheaded the fundraising. He joined The Protein Brewery mid-way. The 15-month fundraise was already in motion. Bosch navigated this leadership transition. Investors assessed the new strategic plan. This demonstrated remarkable agility. His leadership ensured the round's successful closure. Bosch highlighted key fundraising lessons. Customer validation proved crucial. Brand R&D and marketing validated taste and texture. This spoke directly to investors.
Investor conviction strengthened through customer feedback. Promoters spoke directly to investors. This validated commercial due diligence. Sustainability remains a core value. It acts as a "hygiene factor." Fermentation technology offers clear environmental benefits. It requires a fraction of land and water. CO2 footprint is significantly reduced. This commitment to a smaller environmental footprint still holds sway. It remains a key point for all investors. This factor reinforces the company's long-term vision.
The US market presents a significant opportunity. The Protein Brewery seeks strategic partners. These partners operate in sports and active nutrition. They also span the wellness sector. The goal is industrial-scale trials. These collaborations will accelerate market penetration. They will prove Fermotein’s versatility. They will demonstrate its effectiveness. This direct engagement fosters rapid adoption. It secures a foothold in a critical market.
This funding propels The Protein Brewery forward. It readies the company for global leadership. Its mission is clear: redefine food production. Products must be nutritious, sustainable, and scalable. They must be cost-effective. The company is now poised to accelerate. All operational building blocks are in place. The protein and fiber transition gains momentum. A strategic exit is considered more likely than an IPO. This approach offers focused growth. The Protein Brewery leads innovation. It shapes the future of food.